Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models.
OBJECTIVE
Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate cancer mouse models. The aim of this study is to elucidate the pharmacologic activity of Atu027 in inhibiting hematogenous metastasis to the target organ lung in four different preclinical mouse models.


METHODS
Atu027 compared with vehicle or control small interfering RNA lipoplexes was tested in two experimental lung metastasis models (Lewis lung carcinoma, B16V) and spontaneous metastasis mouse models (MDA-MB-435, MDA-MB-231, mammary fat pad). Different dosing schedules (repeated low volume tail vein injections) were applied to obtain insight into effective Atu027 treatment. Primary tumor growth and lung metastasis were measured, and tissues were analyzed by immunohistochemistry and histology. In vitro studies in human umbilical vein endothelial cells were carried out to provide an insight into molecular changes on depletion of PKN3, in support of efficacy results.


RESULTS
Intravenous administration of Atu027 prevents pulmonary metastasis. In particular, formation of spontaneous lung metastasis was significantly inhibited in animals with large tumor grafts as well as in mice with resected primary mammary fat pad tumors. In addition, we provide evidence that an increase in VE-cadherin protein levels as a downstream result of PKN3 target gene inhibition may change endothelial function, resulting in reduced colonization and micrometastasis formation.


CONCLUSIONS
Atu027 can be considered as a potent drug for preventing lung metastasis formation, which might be suitable for preventing hematogenous metastasis in addition to standard cancer therapy.
Silence Therapeutics AG, Robert-Rössle-Strasse 10, Otto-Warburg-Haus 80, Berlin,Germany.
Ansgar
A
Santel
Manuela
M
Aleku
Nadine
N
Röder
Kristin
K
Möpert
Birgit
B
Durieux
Oliver
O
Janke
Oliver
O
Keil
Jens
J
Endruschat
Sibylle
S
Dames
Christian
C
Lange
Mona
M
Eisermann
Kathrin
K
Löffler
Melanie
M
Fechtner
Gerald
G
Fisch
Christiane
C
Vank
Ute
U
Schaeper
Klaus
K
Giese
Jörg
J
Kaufmann
D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000517:prevention & control* / Q000556:secondary*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D042783:Endothelial Cells / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D051379:Mice; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays
D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D034741:RNA, Small Interfering; C561746:Atu027